Podcasts about drug administration

The Food and Drug Administration's controversial regulator is set to exit, amid more criticisms that the agency is stifling promising treatments. Meantime, the AI company Anthropic sues the Pentagon, after the Trump administration labels it a "supply chain risk" after a dispute over surveillance and autonomous weapons. Learn more about your ad choices. Visit megaphone.fm/adchoices

Hey Mama,  Last week, it became clear that if you want to learn how to manage stress naturally as an overstimulated, busy mom, then movement is essential.  You may be wondering, how do I find time for exercise with the busyness of motherhood?  Join me as we look back to part 2 of my interview with Certified Fitness Instructor and Certified Natural Health Practitioner, and sister in Christ, Annemarie Dalton for practical ways to prioritize exercise as a busy mom.   For His Glory, Christen   I would love to hear from you!  >>Leave a Review >>Connect with me:   Sign Up for Manage In The Moment Coaching Call: https://bit.ly/ManageStressInTheMoment   Email me : naturalwellnessforbusymoms@gmail.com  Sign Up to Become an Insider: https://bit.ly/naturalwellnessinsider  Join Our FREE Facebook Community:https://www.facebook.com/groups/1789472588229094  >>Find Related Products Here: https://bit.ly/m/Natural-Wellness-for-Busy-Moms  >> These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. >>I make a small commission when using the links above to purchase items.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and trends shaping the industry landscape, offering insight into the dynamic interplay between scientific innovation, regulatory challenges, and strategic growth.Starting with the recent departure of Vinay Prasad from the U.S. Food and Drug Administration, particularly from his role as director of the Center for Biologics Evaluation and Research (CBER). Prasad's tenure, though brief, left an indelible mark characterized by controversy and debate over regulatory decisions. His leadership coincided with significant advancements in biologics and gene editing technologies, like CRISPR, highlighting the complexities in balancing innovation with safety standards. Under Prasad's guidance, the FDA faced challenges in navigating these rapid advancements while maintaining rigorous oversight to ensure that new therapies are both effective and safe for public use. Prasad's resignation signals potential shifts in regulatory philosophy at CBER. The biotech industry is watching closely to see how new leadership will influence ongoing and future evaluations of biologics. The change presents an opportunity to reassess how regulatory bodies can better adapt to scientific advancements while ensuring that patient safety remains paramount. The issues faced during Prasad's tenure underscore the need for transparent decision-making and open communication with stakeholders, which are vital for maintaining trust in regulatory processes.Meanwhile, Pfizer has made a strategic entry into the Chinese obesity market with the approval of a GLP-1 drug developed alongside Sciwind Biosciences. This approval represents not only a significant step for Pfizer but also underscores a broader global focus on obesity management. The efficacy of GLP-1 receptor agonists in weight regulation has opened up new market opportunities, highlighting the growing importance of metabolic health solutions in addressing public health challenges.In other news, Johnson & Johnson's Tecvayli-Darzalex combination therapy has received its third national priority recognition from the FDA for treating multiple myeloma. This recognition reflects promising Phase 3 trial results and underscores the critical role of innovative combination therapies in improving outcomes for complex hematologic malignancies. The success of such therapies illustrates how targeted approaches can significantly enhance treatment efficacy and patient quality of life.Strategic acquisitions continue to reshape industry dynamics. Servier's $2.5 billion acquisition of Day One Biopharmaceuticals aims to strengthen its rare cancer portfolio, including a promising glioma drug, Ojemda. This move highlights Servier's commitment to addressing unmet needs in pediatric oncology and rare diseases, emphasizing a broader industry trend towards focusing on niche therapeutic areas with high potential impact.Regulatory activities are gaining momentum as well, with the FDA set to end a nine-month hiatus in advisory committee meetings by reviewing AstraZeneca's oral selective estrogen receptor degrader Truqa. As AstraZeneca seeks to enhance its oncology pipeline, this review signals ongoing innovation in hormone-based cancer therapies and reflects a renewed emphasis on bringing novel treatments to market efficiently.Additionally, Glenmark Pharmaceuticals has achieved a significant milestone with FDA approval for its generic version of GSK's asthma inhaler Flovent. This development exemplifies efforts to improve access to respiratory treatments by providing cost-effective alternatives to branded medications, potentially reducing healthcare costs while enhancing patient access.On an international scale, Taiwan has announced a substantial investment plan aimed at bolstering its drugSupport the show

"The disease is increasingly managed as a chronic condition rather than a diagnosis with an immediate terminal outcome. Particularly, with earlier and more effective and sustained treatment options, we can make this disease a very chronic, long-term, livable condition. I want to make sure that patients are aware that this is not a death sentence. This is something that patients can live with for the long term," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about long-term multiple myeloma considerations for oncology nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 6, 2027. Ann McNeill is on the speakers' bureau for Pfizer. This financial relationship has been mitigated. All other planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to management of long-term side effects related to multiple myeloma and treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 401: Multiple Myeloma Treatment Considerations for Oncology Nurses Episode 398: An Overview of Multiple Myeloma for Oncology Nurses Episode 339: A Lesson on Labs: How to Monitor and Educate Patients With Cancer Episode 201: Which Survivorship Care Model Is Right for Your Patient? ONS Voice articles: Effective Care Transitions Are Essential for New Multiple Myeloma Treatments Infection Prevention for Oncology Nurses Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations Nurse-Led Survivorship Programs Sexual Considerations for Patients With Cancer Oncology Nursing Forum articles:  A Qualitative Study of the Experiences of Living With Multiple Myeloma Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study ONS book: Multiple Myeloma: A Textbook for Nurses (third edition) ONS Huddle Cards: Pain Management Sexuality Survivorship Care Plan ONS Learning Libraries: Hematology, Cellular Therapy, and Stem Cell Transplantation Survivorship ONS Symptom Intervention resources: Chronic Pain Fatigue Peripheral Neuropathy American Cancer Society: Living as a Multiple Myeloma Survivor Blood Cancer United: Resources for Healthcare Professionals International Myeloma Foundation: Resources and Support for the Myeloma Community Multiple Myeloma Research Foundation: Empower Patients and the Community To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We do consider myeloma an incurable hematologic malignancy, even though we have had improvements in survival. But just like for any malignancy, our goal is to maximize survival. We want to eliminate as many myeloma cells as we possibly can. And subsequently, we want to improve the quality of life for these patients in the long term. So those are basically our treatment goals. That's what we think of when we're treating patients all throughout their treatment journey." TS 1:39 "It is very typical for patients along their journey to have received several lines of therapy. I think it's important to realize that the cells acquire new mutations, making them more resistant to these further subsequent lines of therapy. We see quicker, more aggressive relapses in those patients with multiple prior lines of therapy. We can see an increase in the CRAB symptoms, which are the calcium elevations, the renal dysfunction, profound anemia, and even bone disease. We can see a rapid rise in the monoclonal protein in the labs or even a very rapid rise in the involved light chain in that serum free light chain assay, so it's important to monitor these labs." TS 9:14 "All oncology nurses are focusing on these survivorship plans now. And I think that's a great thing when you think about a diagnosis of cancer and a survivorship plan, because it means these patients are living a longer time. We still look at long-term health maintenance guidelines depending on the patient's sex and their age. ... I think preventing infection is always going to be something absolutely on the forefront in our survivorship plan with myeloma. I mean, myeloma is an immune system malignancy. The treatments that we have given patients can sometimes, especially in later life therapies, further compromise the immune system. So, we're always looking to prevent serious infection." TS 12:46 "Patients get treatment, especially induction therapy. They may or may not get transplant. They may have been on a very minor maintenance schedule, depending on their age. And they feel really well. And then they decide not to return for their follow-up because they feel so good. I think nurses are critical in the communication aspect of the patient-provider aspect. So, nurses are really the key means of communication. The providers are absolutely important—the physicians, the nurse practitioners and every other member of the team—but I think the nurses have a really special rapport with patients. They're usually the ones providing the education on the treatment regimens. They're managing the toxicity profiles. They're doing all the coordination of care between visits. They are really going to be the ones telling the patient, 'Hey, you're going to feel good and that's a wonderful thing, but you still need to come once a month or once every six weeks or once every two months for your labs.'" TS 15:17  "It has been amazing. The science, the research, the treatments, the approvals from the U.S. Food and Drug Administration. Survivorship has improved dramatically. Let's take the first few years of the new century, right? The five-year survival rate was about 38%. If you then jump to 2015–2019, which is still seven plus years ago, it has doubled. So, we're talking about anywhere from 60%–80% over a five-year survival. So that's an amazing improvement in their five-year survival rate for myeloma." TS 23:28 "Survivorship in myeloma begins at diagnosis, not just after treatment. And I think that because it is managed as a chronic, often relapsing disease, it does require lifelong evolving care. Patients should realize that they will know us for the rest of their lives. We will know everything about you. I always tell them, 'I will know everything about your hobbies, your children, your grandchildren, what you love to do on the weekends.' It's very important that that point is made right at diagnosis, not just after so many lines of treatment. It's very important that we are going to follow these patients throughout their journey." TS 28:18

Welcome back to season 9! We're kicking it off with my first powerhouse guest, whose mission is to bring clarity, safety, and evidence-based understanding to hyperbaric oxygen therapy and integrative wellness. There is a growing wave of interest in longevity and recovery therapies, but also a lot of confusion and misinformation. She breaks down the science (and safety) of one of the most powerful, foundational tools we have for reducing inflammation, accelerating healing, and supporting long-term health. Nicole Garrett is the CEO of Under Pressure Hyperbarics, a premier hyperbaric oxygen therapy center in Beverly Hills recognized for its clinical-grade safety standards and results-driven approach to wellness. With nearly two decades of experience in hyperbaric medicine, her career began as a commercial diver and dive medic, where she first learned the life-saving applications of pressure and oxygen in extreme environments. Since then, Nicole has helped open and operate HBOT centers across the country and has become a trusted leader in the field. Her work bridges the gap between medical-grade hyperbaric therapy and modern holistic wellness, offering patients a safe and effective path to healing, recovery, and long-term vitality. Nicole is especially passionate about educating clinicians, patients, and the wellness community on the science, indications, and proper protocols behind hyperbaric therapy. Today, she leads a multidisciplinary team at Under Pressure Hyperbarics that supports surgical recovery, sports performance, chronic inflammation, and overall health optimization using hospital-grade chambers and evidence-aligned treatment plans. Connect with Nicole via: Email: nicole@underpressure.com Website: Under Pressure Hyperbarics FB: Under Pressure Hyperbarics IG: @underpressurehyperbarics Linked In: Under Pressure Hyperbarics Gift: A special 15% off first-time HBOT session at Under Pressure Hyperbarics for podcast listeners who mention the Holistic Pharmacy episode. Visit https://marinabuksov.com for more holistic content. Music from https://www.purple-planet.com. Disclaimer: Statements herein have not been evaluated by the Food and Drug Administration. Products listed are not intended to diagnose, treat, cure, or prevent any diseases.

In the first episode of Eversio's new Unhinged series, Brandi Garden, Dr. Desiree Caruso, ND, and Samantha Gladish come together for an open and unfiltered conversation about functional mushrooms, health, and the deeper connections between mind, body, and wellness.Samantha's LINKS1. Instagram:https://www.instagram.com/iamsamanthagladish/2. Website: https://www.samanthagladish.com/3. Blog: https://www.samanthagladish.com/blog/TAKE THE QUIZ:If you're not sure where to begin on your mushroom wellness journey, take our Naturopathic Doctor curated Mushroom Wellness QUIZ to find your mushroom match.https://www.eversiowellness.com/pages/take-our-quiz-eversiowellness-youtubeUse code PODCAST15 for 15% off your entire mushroom wellness order at:https://www.eversiowellness.com/discount/PODCAST15JOIN OUR COMMUNITY:Instagram @eversiowellness: https://www.instagram.com/eversiowellness/YouTube @eversiowellness: www.youtube.com/@eversiowellnessTikTok @eversio_wellness: https://www.tiktok.com/@eversio_wellnessFacebook @eversio_wellness: www.facebook.com/eversiowellnessltdQuestions? Contact us here: https://www.eversiowellness.com/pages/contactSign up for our Emails or SMS to be the first to know about product drops, promos, mushroom wellness news!Email List: https://www.eversiowellness.com/pages/sign-up-for-emailsSMS List:https://www.eversiowellness.com/pages/sign-up-for-smsPodcast Website: www.eversiowellness.com for detailed show notesPlease Rate or Share The Eversio Experience Podcast by clicking the 3 dots at the top of the podcast homepage.We appreciate it so much!*The statements, content, and opinions offered in this podcast have not been evaluated by the Food and Drug Administration. The product(s) discussed are not intended to diagnose, treat, cure, or prevent any disease.

The founders of Hershey, Good Humor, Stouffer, Heinz, Kellogg, Kraft, and Birdseye, among others, were pioneers looking to bring clean, hygienic, healthy, and trustworthy products to a market saturated with the opposite. Each specialized in a product, be in chocolate, ice cream, prepared meals, ketchup, cereal, cheese, or frozen foods. Recently we have learned that the grandson of the inventor of Reeses's Peanut Butter cups, owned by Hershey today, has accused the company of destroying the original product, changing "milk chocolate" and "peanut butter" to substances that mirror them. Whereas Milton Hershey sourced fresh milk and used minimal ingredients, modern Hershey products are anything but fresh or even what the label implies. Also, at least 111 substances of unknown safety have been added to foods, drinks and supplements sold in the United States without alerting the US Food and Drug Administration, a new investigation found. This is on top of the exposure that has recently been brought to American foods in general, from food coloring to preservatives - leading companies to change their ingredient lists with a promise of never again lying to consumers. What were companies that attempted to bring purity to a contaminated marketplace, largely resulting from overcrowded cities, has turned ironically into the very thing that they were formed to fight. Now under "trusted brands" the foods that poisons Americans a century ago have made a reemergence.*The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.

Are you treating your Hashimoto's symptoms without ever asking what caused them in the first place? Most women with Hashimoto's spend years chasing symptoms and never get to the real problem. In this episode, we are going upstream. Using the 2010 Deepwater Horizon oil spill as a real-world example, you will see exactly why addressing downstream symptoms without identifying upstream root causes keeps you stuck. Your symptoms are not the problem. They are the result of the problem. In this episode you will learn: Why upstream and root cause mean the same thing and why that matters for your health How your root causes are never just one thing and what to look at instead What your very first step should be after a Hashimoto's diagnosis If you are ready to stop guessing and start identifying your Hashimoto's root causes, this episode is your starting point.

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce the company has released topline results from its Phase 2 clinical study (SKNJCT-003) evaluating the safety and efficacy of its Doxorubicin Microneedle Array (D-MNA) for the non-invasive treatment of basal cell carcinoma of the skin. The company believes the topline data are not only positive but “decision-grade,” meaning they could support an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration in the first half of 2026 and help accelerate potential partnering discussions. Bokhari explained that the SKNJCT-003 clinical trial was designed as a randomized, double-blind, placebo-controlled, multi-center study involving 90 patients diagnosed with nodular basal cell carcinoma. The trial compared two dose levels of the D-MNA treatment with a placebo microneedle array control to assess both safety and therapeutic effectiveness. According to the results, clearance rates improved between Day 29 and Day 57, suggesting continued biological activity of the treatment over time. The higher-dose 200 microgram cohort demonstrated the strongest response by Day 57, achieving a 73% clinical clearance rate and a 40% histological clearance rate. The reported findings reflect analysis of the study's primary and key secondary efficacy endpoints. Medicus Pharma noted that the final Clinical Study Report, which will include full safety analyses and additional procedural observations such as post-excisional biopsy site assessments, is still being compiled and is expected to be completed in the second quarter of 2026. While the final report remains in progress, the company said it does not anticipate any material changes to the efficacy findings reported in the topline results. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #RazaBokhari #Biotech #ClinicalTrials #Phase2Trial #BasalCellCarcinoma #SkinCancer #Doxorubicin #MicroneedleArray #DrugDelivery #FDA #BiotechInnovation #MedicalResearch #CancerTreatment #HealthcareInnovation #Biopharma

Send a textTurn your expertise into income after 50.  Retirement looks different now. With more women exploring second acts - whether driven by economic shifts, changing timelines, or simply a desire for more - many are asking: Where do I start? The answer may already be in you.In this episode of the Ageless Glamour Girls™ Podcast, we explore how seasoned professionals can reposition decades of experience into authority, income, and impact.  Roz Miller-Choice, founder of The Expert Maker® and author of Know It. Share It. Profit., joins us to discuss:• Why experience may be your greatest untapped asset • Moving from employee thinking to expert positioning • Mindset shifts required to monetize what you know • Why your expertise was never meant to be a best-kept secretIf you're navigating midlife reinvention, career repositioning, or building income after 50, this conversation is for you. Cheers to healthy aging and joyful living, Luvvies!ABOUT OUR GUEST:  Roz Miller-Choice - The Expert Maker® is a personal brand strategist, TEDx speaker, author, and award-winning TV host who helps professionals turn knowledge into credible, profitable brands — earning her the name The Expert Maker®.  A former TV anchor, reporter, and producer with CNN, CBS, NBC, and FOX, Roz combines decades of media experience with entrepreneurship training from Cornell University and Harvard Business School. She is the author of the upcoming book Know It. Share It. Profit.: The 3-Step Branding and Marketing Plan to Turn Your Expertise into Profit and leads a creative team that helps experts build visible, authority-driven brands.Her television series The Expert Maker TV is a winner of the 43rd Annual Telly Awards for branding excellence.                                Guest Links:   Pre-Order Book: https://ksp-book.com/Course: knowitshareitprofit.com TEDx Talk: https://youtu.be/fWcK5itKSSYSpecial thanks to our sponsor, Bricker Labs - makers of Liquid Vitamin B12 Blast and Folic Acid, supporting energy and focus in this season. Visit BrickerLabs.com and use our AGG savings code: AGG10. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.Support the showSupport Ageless Glamour Girls™: www.agelessglamourgirls.com www.linkedin.com/in/marqueetacurtishaynes https://www.shopltk.com/explore/AgelessGlamourGirls https://www.youtube.com/@agelessglamourgirls Instagram @agelessglamourgirls Facebook: https://www.facebook.com/agelessglamourgirls Private (AGG) FB Group: The Ageless Café: https://www.facebook.com/groups/theagelesscafe TikTok: @agelessglamourgirls Podcast Producers: Ageless Glamour Girls™ and Purple Tulip Media, LLC

What if you did absolutely everything right: the hormones, the biohacking, the exercise, the nutrition…and STILL ended up needing hip replacement surgery at 54? That is exactly what happened to gerontologist Zora Benhamou, founder of the Hack My Age podcast, and her story is one of the most important and relevant bone health conversations we have had on this show to date. In this conversation, Zora breaks down the critical difference between osteoporosis (bone density loss) and osteoarthritis (joint degeneration) that too many women (and even many doctors) get completely wrong. She walks through the risk factors that set her up for surgery despite a lifetime of doing things right, what an early warning sign of osteoarthritis actually feels like in your body, and why the DEXA scan your doctor ordered may only be telling you part of the story.  We are discussing the REMS scan, a newer ultrasound technology that measures bone quality and strength rather than just density, and she shares the jaw-dropping story of her husband whose results would have landed him on medication he did not need. She covers the science of what forces bones actually require to rebuild, why jumping off a step beats the treadmill, how hormones and bone health are connected, and what protein and minerals actually have to do with fracture prevention. This is also a conversation about bone loss fear and why understanding the full picture is far more powerful than a single scan result. Key take away: bone loss is not a life sentence. Osteoporosis is reversible. And midlife is exactly the right time to take action.  Learn More About Zora Benhamou Instagram ➜ https://www.instagram.com/hackmyage  Website ➜  https://hackmyage.com  Thank you to our show sponsors! QUANTUM UPGRADE: Try Quantum Upgrade completely free for 15 days—no credit card required. Use code NATALIEJILL at checkout on https://quantumupgrade.io/ TIMELINE: Timeline is offering up to 39% off your order of Mitopure! Go to https://timeline.com/NATALIEJILL   Free Gifts for being a listener of Midlife Conversations! Mastering the Midlife Midsection Guide: https://theflatbellyguide.com/ Age Optimizing and Supplement Guide: https://ageoptimizer.com   Connect with me on social media! Instagram: www.Instagram.com/Nataliejllfit Facebook: www.Facebook.com/Nataliejillfit   For advertising inquiries: https://www.category3.ca/  Disclaimer: Information provided in the Midlife Conversations podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before making any changes to your current regimen.  Information provided in this podcast and the use of any products or services related to this podcast does not create a client-patient relationship between you and the host of Midlife Conversations or you and any doctor or provider interviewed and featured on this show. Information and statements may have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease. Advertising Disclosure: Some episodes of Midlife Conversations may be sponsored by products or services discussed during the show. The host may receive compensation for such advertisements or if you purchase products through affiliate links. Opinions expressed about products or services are those of the host and/or guests and do not necessarily reflect the views of any sponsor. Sponsorship does not imply endorsement of any product or service by healthcare professionals featured on this podcast.

When motivation rises, intensity often follows — but more isn't always better. Episode #247

Hey Mama,  Have you ever wondered why you should make time for exercise? Some exercise for health, or to look a certain way, but have you ever considered exercising to manage your stress levels? Over the past few weeks we have been focusing on simple, stackable foundational habits that will help you prepare your body to better receive and manage stress. Exercise is one of the foundational habits you must incorporate to manage stress naturally. And, as Christian Moms, we are called to do everything for God's glory. (Colossians 3:17)  So, how can exercise glorify God? Listen in to today's episode as we re-visit part one of my interview with Certified Fitness Instructor, Certified Natural Health Practitioner, and Sister in Christ, Annemarie Dalton for expert insight.   For His Glory, Christen   I would love to hear from you!  >>Leave a Review >>Connect with me:   Sign Up for Manage In The Moment Coaching Call: https://bit.ly/ManageStressInTheMoment   Email me : naturalwellnessforbusymoms@gmail.com  Sign Up to Become an Insider: https://bit.ly/naturalwellnessinsider  Join Our FREE Facebook Community:https://www.facebook.com/groups/1789472588229094  >>Find Related Products Here: https://bit.ly/m/Natural-Wellness-for-Busy-Moms  >> These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. >>I make a small commission when using the links above to purchase items.

What if the reason time feels like it is speeding up has nothing to do with getting older, and everything to do with how you are living? In this episode of Midlife Conversations, we sit down with world-class event coordinator Jessie Schwartzburg for an energizing and practical conversation about taking time to enjoy your time in midlife. Jessie has spent decades designing unforgettable experiences for high-profile clients, bucket-list travel groups, and corporate powerhouses, and her brain works in a way that will genuinely change how you think about your days. We explore why our brains create such vivid memories during new experiences, how small intentional touches can transform an ordinary moment into something people talk about for years, and what it actually takes to stop feeling like life is passing you by. Jessie also breaks down her personal formula for structuring any day or any trip around the four things she believes are the secret to a long, vibrant life: movement, learning, adventure, and connection. You will walk away with practical, immediately actionable ideas, from planning a memorable birthday lunch to finally booking that group trip you have been putting off. This one is a genuine reset for how you are choosing to spend your time in midlife.  

Angela talks to Professor Stuart Philips, who challenges the long-standing "Anabolic Window" myth, revealing that muscle sensitivity to protein actually lasts up to 48 hours post-exercise rather than a mere 30-minute window.  The conversation cuts through the noise of modern protein obsession, establishing that while the RDA is a baseline, the true sweet spot for muscle synthesis lies between 1.2g and 1.6g per kilogram of body weight. WHAT YOU'LL LEARN: The protein "sweet spot": While the baseline requirement is 0.8g/kg, optimal benefits for muscle maintenance and growth occur between 1.2g and 1.6g per kilogram. The myth of the 30-minute window: The "Anabolic Window" is much larger than previously thought; muscles remain sensitive to protein for up to 48 hours after a workout. Dosage limits: For most people, including perimenopausal and postmenopausal women, 30g to 40g of protein per meal is the effective limit for stimulating new muscle growth. Carbohydrates are essential: Despite modern "carb-phobia," carbohydrates are the primary drivers of high-intensity performance TIMESTAMPS [01:50] The confusion between calculating protein [03:52] The "Baking the Cake" analogy [05:54] Debunking the idea that you can only absorb 20g of protein at a time. [07:18] Addressing Anabolic Resistance and protein needs for women in menopause. VALUABLE RESOURCES ⁠Join The High Performance Health Community⁠ ⁠Click here⁠ for discounts on all the products I personally use and recommend A BIG thank you to our sponsors who make the show possible *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. ABOUT THE HOST Angela Foster is an award winning Nutritionist, Health & Performance Coach, Speaker and Host of the High Performance Health podcast. A former Corporate lawyer turned industry leader in biohacking and health optimisation for women, Angela has been featured in various media including Huff Post, Runners world, The Health Optimisation Summit, BrainTap, The Women's Biohacking Conference, Livestrong & Natural Health Magazine. Angela is the creator of BioSyncing®️ a blueprint for ambitious entrepreneurial women to biohack their health so they can 10X how they show up in their business and their family without burning out. CONTACT DETAILS ⁠Instagram⁠ ⁠Facebook⁠ ⁠LinkedIn⁠ Disclaimer: The High Performance Health Podcast is for general information purposes only and do not constitute the practice of professional or coaching advice and no client relationship is formed. The use of information on this podcast, or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for medical or other professional advice, diagnosis, or treatment. Users should seek the assistance of their medical doctor or other health care professional for before taking any steps to implement any of the items discussed in this podcast. This Podcast has been brought to you by Disruptive Media. ⁠https://disruptivemedia.co.uk/

Amy Kapeller is an Integrative & Functional Nutrition Specialist with advanced training in women's health and autoimmunity. She is the founder of Unbridled Holistic Health -- a functional nutrition practice where she supports women in healing hormones, overcoming burnout, and naturally managing chronic illness. Amy blends functional lab analysis with food and lifestyle medicine, creating personalized, root-cause protocols designed to support each woman's unique body and lived experience. Living with a chronic illness herself, Amy understands what it feels like to be stuck in a cycle of symptoms. She has made it her mission to help women break free from these chronic symptoms so they can truly THRIVE through life again. If you've “tried it all,” are tired of quick fixes, and feel burnt out from health overwhelm—Amy helps you work WITH your body to finally make feeling good sustainable.Amy's story : https://unbridledholistichealth.com/blog//empowered-healingAmy's LINKS:1. From Grandma's Kitchen - Food as Medicine Recipe Guide : https://www.amazon.ca/dp/1069348058?ref=sp_email2. Connect with Amy: https://l.bttr.to/v7PZr3. IG: https://www.instagram.com/unbridledholistichealth/4. Email: unbridledholistichealth@outlook.com5. Practitioner Clinical Mentorship: https://l.bttr.to/6FTGbTAKE THE QUIZ:If you're not sure where to begin on your mushroom wellness journey, take our Naturopathic Doctor curated Mushroom Wellness QUIZ to find your mushroom match.https://www.eversiowellness.com/pages/take-our-quiz-eversiowellness-youtubeUse code PODCAST15 for 15% off your entire mushroom wellness order at:https://www.eversiowellness.com/discount/PODCAST15JOIN OUR COMMUNITY:Instagram @eversiowellness: https://www.instagram.com/eversiowellness/YouTube @eversiowellness: www.youtube.com/@eversiowellnessTikTok @eversio_wellness: https://www.tiktok.com/@eversio_wellnessFacebook @eversio_wellness: www.facebook.com/eversiowellnessltdQuestions? Contact us here: https://www.eversiowellness.com/pages/contactSign up for our Emails or SMS to be the first to know about product drops, promos, mushroom wellnessnews!Email List: https://www.eversiowellness.com/pages/sign-up-for-emailsSMS List: https://www.eversiowellness.com/pages/sign-up-for-smsPodcast Website: www.eversiowellness.com for detailed show notesPlease Rate or Share The Eversio Experience Podcast by clicking the 3 dots at the top of the podcast homepage.We appreciate it so much!*The statements, content, and opinions offered in this podcast have not been evaluated by the Food and Drug Administration. The product(s) discussed are not intended to diagnose, treat, cure, or prevent any disease.

Have you ever left a doctor's appointment with a prescription but still felt like something was missed? If you have Hashimoto's, you are not alone. In this episode, Dr. Aaron Hartman, a triple board-certified physician, breaks down why bad medical advice and Hashimoto's are more connected than most patients realize, and exactly what you can do about it. You will learn: Why medical error affects autoimmune patients more than you think The four root causes behind every autoimmune disease What kind of provider to look for when you feel stuck Hit play to get started.   Episode 129 about LDN with Pharmacist Steve Anderson   Dr. Hartman's book "UnCURABLE - From Hopeless Diagnosis to Defying All Odds"   JOIN THE HEALTH WITH HASHIMOTO'S COMMUNITY Unlock your wellness journey with the free Health with Hashimoto's community! Join a supportive community that's here for you every step of the way. The Health with Hashimoto's community is on Skool: https://www.skool.com/health-with-hashimotos/about   Find all links on my resource page: https://healthwithhashimotos.com/resources/   ABOUT THE PODCAST & ESTHER: The Health with Hashimoto's podcast will help you explore the root causes of your autoimmune condition and discover holistic solutions to address your Hashimoto's thyroiditis. It is hosted by Esther Yunkin, a registered nurse, holistic health educator, and Hashimoto's warrior.   This podcast is for informational and educational purposes. Please discuss any questions or concerns with your healthcare professional. These statements have not been evaluated by the Food and Drug Administration. Products mentioned are not intended to diagnose, treat, cure or prevent any disease.

American officials say they believe China held a nuclear test in 2020, and President Trump reserves the right to do the same, as the New Start arms-control treaty with Russia hits its expiration date this month. Plus, the Food and Drug Administration summarily rejects a flu vaccine from Moderna, before changing course. Learn more about your ad choices. Visit megaphone.fm/adchoices

What if the reason you still feel off (despite trying every diet, supplement, routine, and hormone protocol) is that nobody has ever treated your body as the energy system it actually is? In this conversation, Allison Maslan, who is a classically trained homeopath, founder of Pinnacle Global Network, and a Wall Street Journal bestselling author dives into a conversation that goes far beyond conventional health advice. Allison spent 20 years running her own homeopathic practice, treated thousands of patients, and founded the first homeopathic college in Southern California. She's also in her early 60s, flies trapeze, and is proof that your most powerful chapter can start in midlife. We unpack what homeopathy actually is and why it's been written out of mainstream American medicine, how it can support women navigating menopause and perimenopause (especially those who can't or don't want to use hormones), the science of why your brain literally cannot tell the difference between a vivid visualization and reality, the 1980s study that proved men in their 70s and 80s can physically reverse aging through mindset alone, and Allison's exact Vision Crafting process – the morning ritual she uses to manifest everything from her dream home to business breakthroughs. This episode is for the woman who is tired of only playing defense with her health and is ready to start playing offense with her life with real, science-backed mechanics of how your brain shapes your body and what you can do with that tomorrow morning.  

What really happens when you try to quit sugar — and why perfection isn't required to experience freedom. Episode #246

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big updates for stem cell and islet transplants, new pen option for Zepbound, an implantable insulin pump moves forward and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: I'm just back from MNO DC and I'm exhausted. But it's the best kind of tired. We had an incredible time – hope you can join us in Nashville. With a reminder that we have our first Club 1921 in Nashville – that's our educational dinner series for HCPs and patient leaders. All the info is over at diabetes-connections.com events/     Okay.. our top story this week: XX An "immune system reset" eliminated Type 1, diabetes in mice in a study conducted at Stanford Medicine without immune suppressant medications. This was a combined transplant of blood stem cells and insulin-producing pancreatic islet cells from a donor whose immune profile did not match the recipient. The dual transplant approach both restored insulin production and retrained the immune system. For the full six months of the experiment, the animals did not need insulin injections or immune suppressive medications. Challenges remain using this approach to treat Type 1 diabetes. Pancreatic islets can be obtained only after death of the donor, and the blood stem cells must come from the same person as the islets. It is also unclear whether the number of islet cells typically isolated from one donor would be enough to reverse established Type 1 diabetes. But the researchers are working on solutions, which could include generating large numbers of islet cells in the laboratory from pluripotent human stem cells, or finding ways to increase the function and survival of transplanted donor islet cells. https://scitechdaily.com/stanford-scientists-cure-type-1-diabetes-in-mice-without-insulin-or-immune-suppression/ XX An electronic implant interlaced with islet cells is being looked at to treat type 1. Researchers at the University of Pennsylvania School of Medicine worked with engineers at Harvard University to combine stem-cell biology with soft electronics. They inserted an ultrathin, flexible mesh of conductive wires — thinner than a human hair — into developing pancreatic tissue. As the cells assembled into clusters, the mesh became woven through them. The electronics can record the faint electrical signals produced by the cells that control insulin release. They can also deliver small pulses of electricity back to the cells.   After several days, the cells began to behave more like mature islets. Their internal signalling shifted, neighbouring cells started working in concert and insulin release became stronger and better timed.  Very early on here – and the transplanted cells still need to be protected from being attacked by the immune system. https://www.thetimes.com/uk/science/article/first-cyborg-pancreas-implants-type-1-diabetes-nxkv8r0fp?gaa_at=eafs&gaa_n=AWEtsqeJYYUF9TMR-GgGUG92hPyog-ISeiqGIgdyaaIKKcpvhtoftGiUaaOtQeG0NWI%3D&gaa_ts=699c50d4&gaa_sig=w-PQ0ArosZSznYDSWEzt8aQg4WC0FF5ZFRt9NedO5sSTL2FyWzupH8eSG7RCy2S8TQnlHOeKCudANWm1MNI59w%3D%3D XX Katie Beth (hand) Eledon trial – aaron kowalski post linkedin. Last fall we told you about promising results from Eledon's drug to prevent islet transplantation rejection in type 1 diabetes. The first six patients no longer had to inject or infuse insulin.. the trials continue and this month one of the patients – Katie Beth Hand – began posting about her experiences one month in, on social media, she says she's off basal insulin already and in range 99 percent of the time. She is also encouraging people to learn more about support the islet act https://lnkd.in/e8pQ7_Y7 XX This is a bill introduced last November which would change the wording on pancreatic cell transplants. The problem is that islets are classified as drugs rather than organs, making transplantations difficult for medical teams and centers to preform due to accessibility. Insurance companies are also less likely to provide reimbursements for treatment, which can cost hundreds of thousands of dollars. The official Journal of The Transplantation Society estimates the cost at about $140,000. The bill went to the senate committee of Health, Education, Labor, and Pensions in early November. No other action has been taken since then. https://www.wtoc.com/2026/02/19/bluffton-family-advocates-islet-act-help-diabetic-son/ XX Big change for the obesity drug Zepbound – now available in the multi dose KwikPen. This is a month's worth of doses in a single pen.. and it's multi dose – you can adjust it. Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. Until now, you could only get zepbound in a single dose auto injector or a sing dose vial. In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device. The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro – which is the same medication as zepbound, they're both tirzepitide. https://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.html   XX For years, researchers have observed that people who live at high elevations,  tend to develop diabetes less often than those at sea level. Although the trend was well documented, the biological explanation behind it was unclear. Scientists now say they have identified the reason. Their research shows that in low oxygen environments, red blood cells begin absorbing large amounts of glucose from the bloodstream. Their work showed that when oxygen is limited, red blood cells use glucose to generate a molecule that helps release oxygen to tissues. This process becomes especially important when oxygen is in short supply. The researchers also found that the metabolic benefits of prolonged hypoxia lasted for weeks to months after mice were returned to normal oxygen levels. They then evaluated HypoxyStat, a drug recently developed in Jain's lab that mimics low oxygen exposure. HypoxyStat is taken as a pill and works by causing hemoglobin in red blood cells to bind oxygen more tightly, limiting the amount delivered to tissues. In mouse models of diabetes, the medication completely reversed high blood sugar and outperformed existing treatments. https://www.sciencedaily.com/releases/2026/02/260221060952.htm XX Watching this one closely – Portal Diabetes gets FDA breakthrough device designation for its implantable insulin pump system. This is a system that includes not just a device that's implanted into the abdomen, but also a new, temperature stable insulin. It will work with – quote – "modern" CGM technology with a fully closed loop - and aims to deliver a functional cure for type 1. While reports say Portal's system is the first in the US – there was an implantable pump developed and used by about 500 people worldwide, including about 100 in the US – by MiniMed. Medtronic bought the company and in 2007 they stopped that program. Portal Diabetes expects to begin clinical trials on its combination system around the fourth quarter of 2027. https://www.drugdeliverybusiness.com/portal-diabetes-fda-breakthrough-implantable-insulin-pump/ XX Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. That's the eversense cgm and twist pump. Sequel said its full launch with Eversense 365 makes twiist available with two compatible CGMs. twiist also pairs with the Abbott FreeStyle Libre 3 Plus sensor. Eversense 365, an implantable system, rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. https://www.drugdeliverybusiness.com/sequel-senseonics-full-launch-twiist-eversense/ XX Right back with a Dexcom update, and a look at which type of diet reduces insulin use overall.. right after this: -- Back to the news.. Dexcom is watching for expanded Medicare coverage of its continuous glucose monitors to people with Type 2 diabetes who don't take insulin. CEO Jake Leach told investors on Thursday that the company has been "sitting here waiting for a coverage decision" from the Centers for Medicare and Medicaid Services Dexcom started to see commercial coverage unlock for Type 2, non-insulin users toward the end of last year, Leach said. He expects broader Medicare coverage for that group would allow nearly 12 million people to access CGMs.     In the meantime, the American Diabetes Association updated its guidelines last year to recommend clinicians consider using CGMs for Type 2 diabetes when patients are taking glucose-lowering medications other than insulin. Leach said that real world data the company has been generating supports that decision, and that Dexcom has launched a registry for non-insulin users. https://www.medtechdive.com/news/dexcom-seeks-expanded-medicare-coverage-of-cgms-for-type-2-diabetes/812223/ XX Medtronic's separation of MiniMed is not yet complete.. but continues to move forward. The company has submitted their next pump – MiniMed Flex – to the FDA. This is a pump smaller than the 780G but uses the same reservoirs and infusion sets. It will also work with both the Simplera Sync and Instinct sensors. Medtronic also began a U.S. pivotal study for Vivera, its third-generation algorithm for automated insulin delivery. It also remains set to submit its MiniMed Fit patch pump system to the FDA by the coming fall. https://www.drugdeliverybusiness.com/medtronic-submits-minimed-flex-fda-q3/ XX A study modelling how genes may influence a child's body mass index over time has found that BMI at age 10 and overall growth rate between ages one and 18 might be important factors, as the two are more likely linked to diabetes, high cholesterol, and heart disease in later life. Nearly 66,000 BMI measurements from around 6,300 children and adolescents aged one to 18 were analysed to understand the role of genes.     "Future research is needed to help identify the most effective ages to prevent obesity or poor growth for long-term benefit." https://www.ndtv.com/health/bmi-at-age-10-growth-rate-up-to-age-18-are-important-factors-for-diabetes-heart-disease-study-11125146 XX A low-fat vegan diet—without cutting calories or carbs—may help people with type 1 diabetes significantly reduce how much insulin they need. In a new analysis published in BMC Nutrition, participants following the plant-based plan lowered their daily insulin use by 28%, while those on a portion-controlled diet saw no meaningful change. Researchers say the reduced insulin requirement likely reflects improved insulin sensitivity. The original 2024 study reported additional benefits from the vegan diet. Participants lost an average of 11 pounds and showed improvements in insulin sensitivity and glycemic control. Cholesterol levels and kidney function also improved among those following the plant-based plan. https://www.sciencedaily.com/releases/2026/02/260212234212.htm XX Interesting little tidbit from the Winter Olympic Games.. the World Anti-Doping Agency (WADA) was monitoring GLP drug use. An advisory group that makes recommendations about WADA's list of prohibited substances discussed the status of GLP-1 medications, and added semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) to its monitoring program That means patterns of use of these drugs will be tracked both in and out of competition.  The finding will be used to make recommendations about whether GLP-1 agonists should be added to the prohibited list, the spokesperson explained. While GLP-1 drug use is not currently prohibited, that could change before the next Summer Olympic Games in Los Angeles in 2028, he noted. https://www.medpagetoday.com/popmedicine/cultureclinic/119770 XX That's it for in the news!

It has now been one year of the second Trump administration, with many attacks to sexual and reproductive health, rights, and justice aligning entirely with Project 2025's blueprint. Amy Friedrich-Karnik, Director of Federal Policy at the Guttmacher Institute and Anna Bernstein, Principal Federal Policy Advisor at the Guttmacher Institute, sit down to talk with us about the year's assaults on sexual and reproductive health and rights, LGBTQI+ rights, and science and healthcare by the Trump administration. From day one of their return to office, protections for abortion access put in place by the Biden administration were rolled back. This included several protections for privacy, emergency care, and veteran's access. President Trump immediately pardoned anti-abortion activists who had previously violated the FACE (Freedom of Access to Clinic Entrances) Act and has stopped enforcing the act in most places. Anti-science rhetoric increases, with the Food and Drug Administration endorsing junk-science against mifepristone-- one of the drugs used in a medication abortion. To promote mis- and disinformation, data sets, research, and websites were removed from the internet. The passage of the One Big Beautiful Bill Act defunded Planned Parenthood and set work restrictions on Medicaid coverage. Additionally, the administration froze Title X funding, expanded the already-expanded Global Gag Rule, and issued endless attacks to the transgender community.For more information, check out Future Hindsight: https://www.futurehindsight.com/Support the showFollow Us on Social: Twitter: @rePROsFightBack Instagram: @reprosfbFacebook: rePROs Fight Back Bluesky: @reprosfightback.bsky.social Buy rePROs Merch: Bonfire store Email us: jennie@reprosfightback.comRate and Review on Apple PodcastThanks for listening & keep fighting back!

For people living with osteoarthritis, news about potential new treatments often comes with more questions than answers. In this episode of The Health Advocates, we slow things down to explain what it really means when a company submits a New Drug Application, or NDA, to the U.S. Food and Drug Administration. Steven Newmark is joined by Erich Horsley and Dr. Yusuf Yazici from Biosplice Therapeutics to walk through this important regulatory milestone and why it matters for patients. Together, they break down what an NDA is, what happens during FDA review, and what patients should and should not expect while a therapy is under evaluation. The conversation also explores the current osteoarthritis treatment landscape, why progress in this disease has been so challenging, and what researchers mean when they talk about disease-modifying approaches. Contact Our HostSteven Newmark, Chief of Policy at GHLF: snewmark@ghlf.orgA podcast episode produced by Ben Blanc, Director, Digital Production and Engagement at GHLF.We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.orgListen to all episodes of The Health Advocates on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

As global demand for meat grows, this episode of Duke University's Leading Voices in Food podcast examines cell-cultivated protein—real meat grown from animal cells—and the evolving U.S. policy landscape shaping its future. Host Norbert Wilson (Duke World Food Policy Center) speaks with postdoctoral researchers Kate Consavage Stanley (Duke/Bezos Center for Sustainable Proteins) and Katariina Koivusaari (NC State/Bezos Center) about their article in Trends in Food Science and Technology on U.S. regulatory and legislative activity. The conversation explains the joint FDA–USDA regulatory approach for cell-cultivated meat (FDA oversight through cell cultivation; USDA oversight from harvest through processing, packaging, and labeling) and FDA oversight for cell-cultivated seafood (except catfish). They discuss timelines companies report for approval (often two to three years), the lack of federal public guidance on naming and labeling so far, and how USDA label approvals are currently handled case by case (e.g., "cell-cultivated chicken" and "cell-cultivated pork"). The episode also covers state-level labeling laws and the likelihood of federal preemption if state requirements conflict with federal statutes, as well as a growing wave of state restrictions and bans—Florida and Alabama in 2024, followed by Indiana, Mississippi, Montana, Nebraska, and Texas in 2025—plus funding restrictions in South Dakota and Iowa. The guests explore implications for consumers, interstate commerce, innovation, investment, and U.S. leadership, noting ongoing lawsuits in Florida and Texas and continued legislative activity such as a proposed ban in Georgia.   Interview Transcript Kate, let's begin with you. In the paper, you write about the regulatory frameworks that have been developed for cell-cultivated meat and seafood products in the US. To start, let's talk about what's unique about cell-cultivated products from a regulatory standpoint and how the US Department of Agriculture and US Food and Drug Administration have decided to handle cell-cultivated protein products. Kate - Yes, so as you mentioned in the introduction, Norbert, cell-cultivation is a new technology for use of the food supply. So, the US government had to adapt its existing legal frameworks for food safety regulation. As your listeners may already know seafood is regulated by the FDA, so it was within their scope to also regulate cell-cultivated seafood. The FDA therefore regulates all cell-cultivated seafood products with the exception of catfish. When it came to determining the regulatory approach for cell-cultivated products from livestock, poultry, and catfish, it was a bit more nuanced as the processes and components evolved fell under both USDA and FDA purview. In 2019, the FDA and USDA therefore agreed on a joint regulatory approach where the FDA regulates the early stages of the cell cultivation process, including when those cells are taken from the animal, grown in the bioreactor, and matured into specific cell types such as muscle or fat cells. At the point where those cells are ready to be harvested from the bioreactor to use in a food product, oversight transfers to USDA who oversees that harvesting process as well as food processing, packaging, and labeling. I know this joint regulatory approach may sound complicated, but it's important to note that USDA and FDA already coordinate oversight over other foods in the food supply. I'll give you an example that we all love pizza. A frozen cheese pizza is regulated by the FDA, whereas a frozen pizza with meat toppings like pepperoni is regulated by the USDA. It is therefore not unprecedented that FDA and USDA would agree to jointly regulate cell-cultivated products. And while the process is new, the products go through the same safety checks as other foods in the food supply. In the past few years, we've seen four cell-cultivated meat products go through the joint USDA-FDA regulatory process, meaning they can be sold in the US food supply. And one cell-cultivated seafood product has gone through the FDA regulatory process. Kate, thank you for sharing this. And I've used a pizza example in my class, and it is super complex this regulatory maze that we're talking about. It seems like there has been a lot of collaboration between these two agencies, and so that's important to hear. But it is also the case that it seems challenging for cell-cultivated protein companies to get through this process. Is this a fair assessment and would you elaborate? Kate - Yes, absolutely. We've heard from cell-cultivated companies that it can take two to three years to get through this process. And there certainly is a lot of back and forth between the companies and FDA and USDA. Great, thank you. Katariina, now let's turn to you. How do these regulations extend to labeling and what do we know about the federal government's approach to labeling the sale of cultivated products thus far? Katariina – So, labeling regulations are the most consumer facing part of regulations, really. And they are used to ensure that the product label has information that's truthful, that's not misleading. And that the package has sufficient information and consistent information also across products so that the consumer can make an educated decision on what product they want to purchase. And you'd think that how you label the product or just how you call the product on the label would be simple. But there are certain regulations in place that define how food items can or cannot be called. Now, when it comes to cell-cultivated products, as you and Kate mentioned, they are novel in the food supply. So, there is not a long-established term or nomenclature on how we should call these products. The federal regulators, FDA and USDA, to date have not released any public guidance either on how these products should be called on the label. The USDA did release an advanced notice of proposed rulemaking back in 2021, requesting comments from stakeholders on how these products should be labeled. And the FDA has also requested comments when it comes to labeling cell-cultivated fish and seafood. But to date, no guidance has been published yet. Kate gave an overview of the regulatory process between FDA and UFDA when it comes to labeling this product products. The USDA oversees labeling cell-cultivated meat, and the FDA oversees labeling cell-cultivated fish and seafood. The USDA has a pre-market approval process for labels, similarly to conventional meat industry. So, whenever a company wants to bring to market a new product, they first submit their label to the USDA. And the USDA reviews it and make sure that they agree with the language used in the label. The FDA does not have a similar pre-market approval process for labeling fish or seafood or cell-cultivated fish or seafood. So, currently cell-cultivated meat labels are approved on a case-by-case basis. And we can see from the products that have gone through the regulatory review so far that the USDA seem to approve the use of 'cell-cultivated' as a qualifying term, together with a meaty term such as chicken or pork. So, the products that we've seen approved to date or brought to market to date are called cell-cultivated chicken or cell-cultivated pork. This is really helpful to know what's happened at the federal level. We also know that there are several actions happening at the state level, so several states have proposed their own laws outlining how and what to label these products. Katariina, can you talk us through what this study regarding state labeling? Katariina - To date, about half of the US states have enacted or proposed their own labeling legislation on cell-cultivated products. Missouri became the first state in 2018, so well before any of these products was available on the market. And they specifically prohibited the use of word meat unless the food was from harvested production livestock or poultry. Restricting, therefore, the use of meat not only on cell-cultivated, but also on other alternative protein products such as plant-based meat analogs or fermentation derived proteins. And this is true for many state level labeling laws. That they are applicable not only to cell-cultivated meat, but also other alternative proteins aiming to mimic meat. In addition to Missouri, there are six other states that prohibit the use of meat or meat related terms, such as chicken or pork. Now, the other group of states that have restrictions on cell-cultivated meat labeling do not concentrate on prohibiting the use of word meat, but they require the use of qualifying terms or other additional language that clearly states that the product does not come from livestock or poultry. And this group of states, there are 18 states, have quite a bit of variation in what kind of qualifying terms they require to be used. And I thought I'd give a couple of examples here. For example, Indiana requires the package to include the phrase this is an imitation meat product. Iowa requires the product to be labeled with qualifying terms such as cell-cultivated, cell-cultured, fake, grown in a lab, imitation, lab grown, lab created, meat free, or meatless. What's interesting though is that the federal statutes that regulate the US food supply have actual language that prevents states from establishing laws or regulations that conflict with or are additional to the federal labeling regulations. So, this means that the state level labeling laws are actually likely to be preempted if they conflict with the federal regulations. So, we've only talked about labeling so far. Kate, I want to go back to you. More recently, we've seen a number of states propose greater restrictions on these products. Can you describe these attempts to restrict cell-cultivated meat and their immediate implications? And how have cell-cultivated companies and other stakeholders responded? Kate - In the past few years we've seen quite a few attempts by states to ban or restrict cell-cultivated meats. And these attempts fall into two buckets: bans that aim to restrict the manufacturer sale or distribution of cell-cultivated products and bans that aim to limit the use of state funding to support these products. In 2024, Florida was the first state to pass a ban on the manufacture, sale, and distribution of cell-cultivated meats. Alabama followed shortly thereafter. In 2025, five more states passed similar bans on cell-cultivated products, including Indiana, Mississippi, Montana, Nebraska, and Texas. And many other states proposed bans that ultimately didn't pass. The language on what is banned differs some between states. For instance, Texas only bans the sale of cell-cultivated products. Whereas Florida and others also ban cell-cultivated manufacturing and distribution. But the core message in all these bans is similar. Cell-cultivated meats are not welcome in those states. The time span for the bans differs too. So, Indiana and Texas have two-year bans while Florida and other states passed indefinite bans. And we've seen two states, South Dakota and Iowa pass legislation to restrict the use of state funding to support cell-cultivated products. What's frustrating about these bands and confusing for those in the alternative protein sector is that cell-cultivated technology is largely still in the early stages. Yes, as I mentioned earlier, five products have passed through the regulatory process. But these products have mainly been made available in small tasting events. And only one has actually made it to retail. Most Americans have never had a chance to actually try these products. So, it begs the question, why is there such resistance? State bans on these products mean that Americans will not have the chance to decide for themselves if they like these products, or if and how they want to incorporate them into what they eat. Another big concern is that these bans create a fragmented policy landscape that's challenging for cell-cultivated startups, especially, to navigate. And it raises a lot of concerns about cross state sales. Concerns like these are the basis for two lawsuits against cell-cultivated bans in Florida and Texas. Those lawsuits are still playing out in court, so we don't yet know how those may Kate, this is really fascinating. And as both you and Katariina described, there's a patchwork of policies and a complex landscape for these companies to navigate. It has the potential of keeping consumers from even trying the products, as you've already suggested, when they're made available. And what I'm hearing from both of you is that this is an ongoing project. So even though there's a paper that's published now, it seems like there will be opportunities to keep going back as new laws and new regulations and new lawsuits are decided. So, this is a policy space that we need to keep an eye on. That's something I want to pick up on this last question. In closing, what does this legislation mean for consumers and the future of cell-cultivated products in the US and even globally? Katariina, let's begin with you. Katariina - Yes. In addition to impeding interstate and international commerce of cell-cultivated products, these bans could negatively impact the US investment climate on these products and technologies. For example, China has included developing cell-cultivated meat in their five-year plan. Within Europe, there's some variation. Some countries are being rather supportive of these technologies and products, whereas others have tried to ban them similarly to some US states. But I think it's important to note that even with some states in the US banning these products, the US will still likely remain a significant market area for cell-cultivated products. And it still takes significant investment and infrastructure to produce the products on a large scale enough to even reach the whole country. Another really important thing to mention here is that the global demand for meat is growing. If we look at global population forecasts, global meat or protein consumption forecasts, we need these alternative proteins. Not only cell-cultivated meat, but also for example, plant-based meat alternatives to help meet the increasing demand for protein and complement conventional meat supply. Kate, what about you?   Kate – I agree with everything that Katariina said. To add on to her points, I note that the US has been a leader in the cell-cultivated research development and innovation spaces to date. We are one of only a few countries that have both developed a framework for regulating these products and had products successfully pass through that process. The bans tell a different story, and they may restrict US innovation in the cell-cultivated space because companies will be limited to only the states where they can produce and sell these products. What this means for US leadership in the space remains to be seen. However, one could ask will cell-cultivated companies choose to set up shop in the US versus another country that isn't facing such legal challenges? We don't yet know the answer to that. You also mentioned consumers. We don't yet know about how these bans and the media surrounding them may influence consumer perceptions of cell-cultivated foods. Products, as you said, they've never even really had the chance to try. But these bans will certainly restrict consumer access to these products in certain states, and the varying state approaches to labeling that Katariina described are likely to confuse consumers. Going back to something you mentioned earlier, Norbert, we're excited to have this paper out in the world. But this work is certainly continuing to evolve. Just recently, a senator in Georgia proposed a new ban on cell-cultivated meat in the state, and other countries have faced similar legislative challenges against these products. So, we'll be watching and learning as these challenges continue to play out. Bios Katariina Koivusaari, Ph.D. is a postdoctoral researcher at the Bezos Center for Sustainable Protein at North Carolina State University. Her work focuses on stakeholder engagement and the regulatory and policy landscape of alternative proteins, including cell-cultivated products, fermentation-derived proteins, and plant-based proteins. She received her Ph.D. in Public Health Nutrition and M.Sc. in Food Sciences from the University of Helsinki. Prior to her current role, she worked in the biotechnology industry as a Senior Regulatory Scientist, where she focused on scientific strategy and regulatory affairs related to cell-cultured human milk ingredients. Katherine (Kate) Consavage Stanley, Ph.D., serves as a postdoctoral associate within the World Food Policy Center at the Sanford School. In this role, Kate supports Duke's research for the Bezos Center for Sustainable Protein housed at NC State. Her research seeks to detail the complexities of the consumer, market, and policy landscapes for alternative protein products. Kate holds a Ph.D. from Virginia Polytechnic Institute and State University where her research focused on how diverse U.S. food and health systems actors can support sustainable diet transitions through promoting plant-rich dietary patterns and reducing red and processed meat intake. She has also published scholarly work on digital food and nutrition literacy, sugary beverage media campaigns, and incorporating sustainability considerations into dietary guidelines, among others. Prior to starting her doctoral studies, Kate worked for the U.S. Agency for International Development (USAID) where she developed technical, communications, and advocacy-focused materials on key nutrition and maternal and child health issues. Kate holds a Master of Science in global health from Georgetown University and a Bachelor of Science in biology from Emmanuel College.      

About this episode: A recent analysis of FDA documents has found that the agency has historically regulated mifepristone—a medication commonly used to terminate pregnancy—based on available scientific evidence and without ideological bias. In this episode: Caleb Alexander, an author of the study, discusses these findings and their implications for a possible new review of the medication by FDA. Guests: Dr. G. Caleb Alexander, MS, is a practicing internist and drug safety expert at the Johns Hopkins Bloomberg School of Public Health. Host: Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health. Show links and related content: The US Food and Drug Administration's Regulation of Mifepristone—JAMA Study: FDA Regulation of Abortion Drug Mifepristone from 2011 to 2023 Shaped by Evidence and Caution—Johns Hopkins Bloomberg School of Public Health F.D.A. Decisions on Abortion Pill Were Based on Science, New Analysis Finds—New York Times What Is Mifepristone, aka "The Abortion Pill"?—Johns Hopkins Bloomberg School of Public Health What's at Stake for Access to Medication Abortion and the FDA in the Supreme Court Case FDA v. the Alliance for Hippocratic Medicine?—KFF Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Hey Mama,  Do you want to learn how to find time to exercise as a busy mom? Studies show moving your body is not only essential for your physical health, but also for your mental health. As moms, it can be difficult to find the time to exercise with all of the responsibilities we have.  Maybe you know exercise is good for you, but you are not sure where to start. Maybe you desire to be active like you used to, but your body is different, and you can't do what you used to.  No matter your age and stage, Mama, you can move your body and you should move your body because movement improves your mental health. Your mental health matters, for you and your family. Join me today as I share with you three practical tips to make time for exercise as a busy mom.   For His Glory, Christen   I would love to hear from you!  >>Leave a Review >>Connect with me:   Sign Up for Manage In The Moment Coaching Call: https://bit.ly/ManageStressInTheMoment   Email me : naturalwellnessforbusymoms@gmail.com  Sign Up to Become an Insider: https://bit.ly/naturalwellnessinsider  Join Our FREE Facebook Community:https://www.facebook.com/groups/1789472588229094  >>Find Related Products Here: https://bit.ly/m/Natural-Wellness-for-Busy-Moms  >> These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. >>I make a small commission when using the links above to purchase items.

The Food and Drug Administration will review Moderna's new flu vaccine after reversing course. Medicare Advantage growth in 2026 is trailing prior years. And Amazon is expanding same-day prescription delivery to nearly 5,000 cities nationwide. Those stories and more on today's episode of The Gist Healthcare Podcast. Hosted on Acast. See acast.com/privacy for more information.

Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman, Senior Editor Sue Sutter, and Editor-in-Chief Nielsen Hobbs discuss a series of US Food and Drug Administration proposals for user fee program changes that would advance President Trump's priorities and the concerns they raise (:31). They also consider the impact of the agency's decision to review Moderna's mRNA flu vaccine application shortly after refusing to file it and using accelerated approval for one of the proposed indications (8:37), as well as ideas for sponsors wondering if their development advice is still good (25:24). More On These Topics From The Pink Sheet US FDA Proposing White House-Aligned Policies For User Fee Agreements: https://insights.citeline.com/pink-sheet/pathways-and-standards/user-fees/us-fda-proposing-white-house-aligned-policies-for-user-fee-agreements-D5JWRDGLCFBT7CYT3FGK3JAZNI/ After Moderna Flu Vaccine, Is US FDA's Accelerated Approval A Pathway Or A Pressure Valve?: https://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/after-moderna-flu-vaccine-is-us-fdas-accelerated-approval-a-pathway-or-a-pressure-valve-EWMFKFWO3BB3JA6CQHC4E3JWPA/ Moderna Flu Vaccine Debate Could Resolve With Postmarket Study, FDA's Makary Suggests: https://insights.citeline.com/pink-sheet/vaccines/moderna-flu-vaccine-debate-could-resolve-with-postmarket-study-makary-suggests-Y3R657N2JZABRGFOSKADM33YA4/ Horse Trading? Oz, Bourla Exchange MFN Codification, Vaccine Collaboration Requests: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/horse-trading-oz-bourla-exchange-mfn-codification-vaccine-collaboration-requests-X6UDDVOSMRBSTO5WC224IN6PTE/

Today's Headlines: Billionaire retail mogul Les Wexner testified before Congress about his ties to Jeffrey Epstein — but instead of appearing on Capitol Hill, lawmakers traveled to his Ohio mansion, where the 88-year-old was deposed with family members present. Notably, no Republicans on the House Oversight Committee showed up. Wexner, who once granted Epstein power of attorney, said he was “naive, gullible, and foolish” and claimed he was conned, despite building a multibillion-dollar empire. It wasn't the only billionaire hot seat of the day. Mark Zuckerberg testified in a landmark trial against Meta over allegations the company knowingly made its platforms addictive and harmful to children. The case could influence more than 1,500 pending social media addiction lawsuits. Meanwhile, The New York Times reported Meta has set aside $65 million to back state-level politicians friendly to the AI industry through new super PACs in Illinois and Texas — timing that feels… strategic. In federal agency cleanup news, the U.S. Food and Drug Administration removed a webpage warning against bogus autism “treatments” like chlorine dioxide and raw camel milk, calling it routine housekeeping. On the foreign policy front, Donald Trump met with advisers to discuss Iran, as mixed signals emerge from nuclear talks in Geneva and two U.S. aircraft carriers sit in the Mediterranean. The administration also plans to withdraw roughly 1,000 U.S. troops from Syria over the next two months, though officials say the move is “conditions based.” Meanwhile, a potential U.S. arms sale to Taiwan is reportedly in limbo ahead of Trump's planned meeting with Xi Jinping in Beijing. Back home, New York City Mayor Zohran Mamdani announced the city will resume clearing homeless encampments following at least 19 deaths during a recent cold snap, with outreach led by homeless services rather than police. Resources/Articles mentioned in this episode: AP News: Billionaire Les Wexner says he was 'duped' by adviser Jeffrey Epstein, 'a world-class con man' Axios: Zuckerberg testifies in landmark social media addiction trial NYT: Meta Begins $65 Million Election Push to Advance A.I. Agenda ProPublica: Chlorine Dioxide, Raw Camel Milk: The FDA No Longer Warns Against These and Other Ineffective Autism Treatments Axios: Trump meets with top Iran advisers as war threat grows WSJ: U.S. Is Withdrawing All Forces From Syria, Officials Say WSJ: U.S. Arms Sale to Taiwan in Limbo Amid Pressure Campaign From China AP News: Mamdani reboots homeless encampment sweeps in New York City Subscribe to the Betches News Room and join the Morning Announcements group chat. Go to: ⁠⁠⁠betchesnews.substack.com Morning Announcements is produced by Sami Sage and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

The twists and turns continue at the nation's health agency, where this week's announcements included notice that the Food and Drug Administration will review Moderna's new flu vaccine after all and that a handful of top agency officials are getting new jobs.Those developments and others can be traced to a White House looking to shake things up before the midterms — and win over voters on health care. Tami Luhby of CNN, Shefali Luthra of The 19th, and Lauren Weber of The Washington Post join KFF Health News' Mary Agnes Carey to discuss these stories and more. Visit our website for a transcript of this episode.Plus, for “extra credit” the panelists suggest health policy stories they read this week that they think you should read, too:  Mary Agnes Carey: Politico's “Why Congress Failed To Reach an Obamacare Deal,” by Robert King and Simon J. Levien. Lauren Weber: NiemanLab's “The Atlantic's Elizabeth Bruenig on Her ‘Hypothetical,' Heavily Reported Measles Essay,” by Laura Hazard Owen. Tami Luhby: The City's “NewYork-Presbyterian Nurses Reject Contract by Overwhelming Margin,” by Claudia Irizarry Aponte and Ben Fractenberg. Shefali Luthra: NPR's “Minneapolis Doctors Warn of Lasting Medical Effects, Even After ICE Agents Leave,” by Jasmine Garsd. 

It's Thursday, February 19th, A.D. 2026. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Jonathan Clark British preacher challenges buffer zones around abortion mills A preacher in Britain is challenging the country's abortion buffer zones which effectively censor the Bible. Officials arrested, charged, and convicted Stephen Green for holding a sign with a Bible verse near an abortion mill in 2023. The verse was Psalm 139:13 which says, “For You formed my inward parts; You knitted me together in my mother's womb.” Green stated, “As a Christian, I should be able to preach freely all over the land. Psalm 139 is about how we all belong to God from conception. Buffer zones and this conviction [are] a direct attack on the Bible and free speech.” Elon Musk endorsed new conservative political party in England Billionaire Elon Musk endorsed a new conservative political party in Britain last week. On Friday, Member of Parliament Rupert Lowe launched the Restore Britain Party. Musk shared the launch video on X which has received nearly 40 million views.  The party is devoted to ending mass immigration and the creeping Islamification of Britain. Rupert Lowe also stated the party will openly recognize the country's Christian heritage.  Listen. LOWE: “Restore Britain will openly recognize the Christian heritage that shaped this country's moral and civic foundation. (applause) Duty, restraint, forgiveness and, most importantly, fairness. These values created a high trust society. “Restore Britain will end the creeping Islamification of Britain. (applause)  Unfettered immigration from Islamic countries will end. (applause) Britain is a Christian country, and under Restore Britain government, it will remain a Christian country.” (applause) Church of England votes against blessing homosexual couples Last week, the Church of England  voted against proposals to allow blessing services for homosexual couples. The General Synod did not shut the door on the issue though, voting to investigate it in the future.  The move keeps the church from performing marriage services and blessing services for people living in unnatural relations. However, the Church of England's rules already allow blessing prayers within regular Sunday services for such couples.  Proverbs 25:26 says, “Like a muddied spring or a polluted fountain is a righteous man who gives way before the wicked.” Franklin Graham preached in world's southernmost city Evangelist Franklin Graham  preached in Ushuaia, Argentina. It's known as the southernmost city in the world. Listen. GRAHAM: “What makes Ushuaia so special are the people. We love the people. If you can't remember anything else tonight, remember this: God loves you. God sent His Son, Jesus Christ, to take our sins. We deserve death. We're guilty of sin. “Bartimaeus had no hope. There are many of you here tonight. You have no hope. Now, Bartimaeus cried at the right time. Jesus was passing by. The Bible says that ‘God so loved the world that He gave His only begotten Son that whosoever believeth in Him should not perish, but he should have everlasting life.' “Will you invite Christ into your heart? Will you trust Him? Come. Come to Jesus.” Hundreds of people turned to Christ through the evangelistic outreach event. Graham wrote on X, “We give God the glory for each one who responded to the invitation to repent of their sins and put their trust in Jesus Christ as their Lord and Savior.” Eighty-two percent of South Americans identify as Roman Catholic, but evangelicalism has been growing in recent decades.    Graham also plans to visit Peru next month. 21 states challenge mail-order abortion kill pills In the United States, 21 states and 60 members of Congress are challenging mail-order abortion drugs. Louisiana initiated the case, challenging a Biden-era rule from the U.S. Food and Drug Administration. The rule removed the in-person dispensing requirement for the abortion drug mifepristone.  Erik Baptist with Alliance Defending Freedom stated, “The Biden FDA's unlawful authorization of mail-order abortion drugs was meant to be a loophole around states that choose to protect life.” 41-year-old mother Olympic bobsledder wins gold (audio Olympic theme song) American Olympic bobsledder Elana Meyers Taylor  won her first gold medal on Monday. The 41-year-old mother triumphed in the women's monobob event at the 2026 Winter Olympics in Italy.  She is now the oldest gold medalist in an individual Olympic event. After the victory, she said this on Instagram: “The moment we prayed for. Glory to God.” Norway has won the most gold medals Nearly 2,900 athletes from over 90 countries are competing in the 2026 Winter Olympics.  So far, Norway has won the most gold medals and the most medals overall. In the medal count, Norway is followed by Italy and the U.S. A podium finish can mean big prize money for athletes. A gold medalist from the U.S. can win $38,000. Athletes from Singapore can make the most for winning an individual event at $792,000.   Christian missionaries sharing Christ & Bibles in Olympic crowds And finally, Evangelicals are sharing the Gospel at the Winter Olympic Games this year. Hundreds of Southern Baptists alongside International Mission Board missionaries are joining the crowds to share Christ and distribute Bibles. Karen Herfurth is in Italy with a group from Mt. Zion Baptist Church in Huntsville, Alabama. She said, “This is a chance for Southern Baptists to reach more people and impact more lives! We may never know the difference this makes until we are in Heaven.” Close And that's The Worldview on this Thursday, February 19th, in the year of our Lord 2026. Follow us on X or subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com.  Plus, you can get the Generations app through Google Play or The App Store. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

Tired of thyroid meds eating into your budget every month? You're not stuck with high prices—especially with Hashimoto's or hypothyroidism. This episode breaks down three real options to how to save money on thyroid medication so you can stay consistent with your levothyroxine (or other thyroid needs) without the stress. The core message: A quick comparison puts you back in control as the CEO of your health. You'll discover: How GoodRx coupons stack up against Cost Plus Drugs' transparent generics and TrumpRx's brand discounts (with actual price examples for common doses). Why generics often win on cost, but sticking to one manufacturer matters for feeling stable. How to pick the best fit for your life—local pharmacy loyalty, mail-order ease, cash vs. insurance, or whatever season you're in. No overwhelm, just practical RN advice (including my small-town pharmacy wins). Hit play and check prices on your next refill—you've got this!   Links: TrumpRx - https://trumprx.gov  GoodRx - https://www.goodrx.com  Cost Plus Drugs - https://www.costplusdrugs.com    JOIN THE HEALTH WITH HASHIMOTO'S COMMUNITY Unlock your wellness journey with the free Health with Hashimoto's community! Join a supportive community that's here for you every step of the way. The Health with Hashimoto's community is on Skool: https://www.skool.com/health-with-hashimotos/about   Find all links on my resource page: https://healthwithhashimotos.com/resources/   ABOUT THE PODCAST & ESTHER: The Health with Hashimoto's podcast will help you explore the root causes of your autoimmune condition and discover holistic solutions to address your Hashimoto's thyroiditis. It is hosted by Esther Yunkin, a registered nurse, holistic health educator, and Hashimoto's warrior.   This podcast is for informational and educational purposes. Please discuss any questions or concerns with your healthcare professional. These statements have not been evaluated by the Food and Drug Administration. Products mentioned are not intended to diagnose, treat, cure or prevent any disease.

The Food and Drug Administration agreed to begin a review of biotech company Moderna's application to make a new seasonal flu shot available. The decision comes after the FDA initially refused to review the company's application. It's a back and forth that reveals increased turmoil within the agency. WSJ's Liz Essley Whyte takes us inside the FDA's unexpected reversals and explores what's next for the mRNA flu vaccine. Jessica Mendoza hosts.  Further Listening: - The FDA Commissioner on Vaccines and Public Trust - Breakfast Battle: The Cereal Industry vs MAHA Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

A partial government shutdown is impacting the Department of Homeland Security, leaving essential personnel to work without pay as Republicans and Democrats remain divided over funding. The debate intensified following controversial immigration enforcement actions in Minneapolis & Los Angeles that have sparked anti-ICE protests and demands for stricter oversight of federal agents. Rep.Tony Gonzales (R-TX), whose district covers 800 miles of the southern border, joins to discuss the DHS funding standoff, the focus on the removal of criminal illegal aliens, and why he believes the border is more secure now than under the previous administration.The Trump administration is once again taking a closer look at the American diet and what's in it. As part of the Department of Health and Human Services “Make America Healthy Again” agenda, the Food and Drug Administration is targeting the longstanding “Generally Recognized as Safe” (GRAS) rule, which allows food companies to self-certify ingredients without federal oversight. FDA Deputy Commissioner for Human Foods Kyle Diamantas joins the Rundown to discuss how Americans can avoid potentially harmful processed ingredients and the steps Washington is taking to eliminate them. Plus, commentary by FOX News Contributor, Richard Fowler. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In 1980, toxic shock syndrome (TSS) emerged as a public health crisis among women who used tampons. There were hundreds of cases, and The Centers for Disease Control linked deaths from TSS to super-absorbent tampons.The Food and Drug Administration responded by assembling a ‘Tampon Task Force' in 1982 to develop safety standards. A researcher called Nancy King Reame was recruited to run the independent laboratory testing. Her work helped establish the first national absorbency standards for tampons. Golda Arthur speaks to Nancy King Reame. Eye-witness accounts brought to life by archive. Witness History is for those fascinated by the past. We take you to the events that have shaped our world through the eyes of the people who were there. For nine minutes every day, we take you back in time and all over the world, to examine wars, coups, scientific discoveries, cultural moments and much more. Recent episodes explore everything from the death of Adolf Hitler, the first spacewalk and the making of the movie Jaws, to celebrity tortoise Lonesome George, the Kobe earthquake and the invention of superglue. We look at the lives of some of the most famous leaders, artists, scientists and personalities in history, including: Eva Peron – Argentina's Evita; President Ronald Reagan and his famous ‘tear down this wall' speech; Thomas Keneally on why he wrote Schindler's List; and Jacques Derrida, France's ‘rock star' philosopher. You can learn all about fascinating and surprising stories, such as the civil rights swimming protest; the disastrous D-Day rehearsal; and the death of one of the world's oldest languages.(Photo: Tampons. Credit: Getty Images)

What if everything the government told you to eat for 30 years was literally backwards? If you're over 45 and you've been confused by decades of conflicting nutrition advice, this conversation is for you. You've been told to eat fat-free and then full-fat. You've been told carbs are evil and then that you need them. The food pyramid told us to load up on bread, pasta, and rice while keeping fat to a bare minimum. We followed that advice. And we got fatter, sicker, and more inflamed than ever. Now the entire framework has been flipped upside down.  This isn't your fault. The recommendations actually were wrong, and they're finally correcting course. Nutrition has somehow become political. The real reason the old food pyramid was designed the way it was has nothing to do with what's actually healthy for your body. Spoiler alert: it was about fear of fat, preventing deficiency, and keeping people fed cheaply. Optimization? That wasn't even on the radar. In this episode, Natalie sits down with registered dietitian Keri Glassman to break down the 2025 dietary guidelines, how the government's shift from "preventing disease" to "supporting optimal health" changes literally everything about nutrition that we've seen for decades, the specifics that the new guidelines finally got right (and the nuances they still missed), the seed oil debate and what actually matters, how GP1's are becoming genuinely life-changing for some women, and why the glamorization of eating disorders on social media connected to these drugs is deeply concerning…and more!  But understanding what changed is only half the battle. The bigger conversation is about learning to trust your own body's signals, understanding that your nutrition needs over 45 are different than at 25, and finding what actually works for YOUR individual situation instead of following yet another set of rules.   Catch the full episode on YOUTUBE HERE: https://bit.ly/MidlifeConversationsYouTube    Learn More About Keri Glassman Instagram ➜ https://www.instagram.com/keriglassman  Website ➜  https://nutritiouslife.com/  Thank you to our show sponsors! BIOPTIMIZERS: Get the digestive enzymes I take with every meal here https://www.bioptimizers.com/nataliejill  Free Gifts for being a listener of Midlife Conversations! Mastering the Midlife Midsection Guide: https://theflatbellyguide.com/ Age Optimizing and Supplement Guide: https://ageoptimizer.com   Connect with me on social media! Instagram: www.Instagram.com/Nataliejllfit Facebook: www.Facebook.com/Nataliejillfit   For advertising inquiries: https://www.category3.ca/  Disclaimer: Information provided in the Midlife Conversations podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before making any changes to your current regimen.  Information provided in this podcast and the use of any products or services related to this podcast does not create a client-patient relationship between you and the host of Midlife Conversations or you and any doctor or provider interviewed and featured on this show. Information and statements may have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease. Advertising Disclosure: Some episodes of Midlife Conversations may be sponsored by products or services discussed during the show. The host may receive compensation for such advertisements or if you purchase products through affiliate links. Opinions expressed about products or services are those of the host and/or guests and do not necessarily reflect the views of any sponsor. Sponsorship does not imply endorsement of any product or service by healthcare professionals featured on this podcast.  

The U.S. Food and Drug Administration announced recently that it will not review Moderna's mRNA flu vaccine, despite late-stage trials showing it was safe and effective. The rejection has many in and outside the industry concerned about the Trump administration's approach to vaccine development and recommendations. Amna Nawaz discussed more with Michael Osterholm. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Why shorter fasts often stop working once insulin resistance is established — and what therapeutic fasting is actually designed to do. Episode #245

Hey Mama,  Over the past couple weeks, I have talked with you about the importance of hydration for your physical and mental wellbeing. Not only does hydration improve your body's ability to receive and manage stress well, but it is essential to living a vibrant life.  Last week, I shared with you practical ways to incorporate more water into your day, even as a busy mom. Today, I want to share with you the ultimate water you need to combat stress, anxiety and overstimulation as a mom.   For His Glory, Christen   I would love to hear from you!  >>Leave a Review >>Connect with me:   Sign Up for Manage In The Moment Coaching Call: https://bit.ly/ManageStressInTheMoment   Email me : naturalwellnessforbusymoms@gmail.com  Sign Up to Become an Insider: https://bit.ly/naturalwellnessinsider  Join Our FREE Facebook Community:https://www.facebook.com/groups/1789472588229094  >>Find Related Products Here: https://bit.ly/m/Natural-Wellness-for-Busy-Moms  >> These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. >>I make a small commission when using the links above to purchase items.

A.M. Edition for Feb. 9. The latest revelations from the Epstein files bring down the top aide to Britain's Prime Minister. Will Keir Starmer be next? WSJ U.K. correspondent Max Colchester weighs in. Plus, Novo Nordisk shares are rallying after the U.S. Food and Drug Administration threatened to restrict access to the ingredients needed for knockoffs of popular GLP-1 medicines like WeGovy. And SpaceX delays its Mars plans to focus on the Moon instead. Luke Vargas hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices